Description
The National Heart, Lung, and Blood Institute (NHLBI), in partnership with the National Science Foundation (NSF) and the NIH Office of Behavioral and Social Sciences Research (OBSSR), hosted a workshop on April 1-2, 2019 to discuss the potential transformation of NIH-funded clinical trial research by leveraging digital technologies including data analytics. Development of diverse digital technologies and analytics has impelled a paradigm shift in how clinical trials can be conducted. This development points to opportunities to advance the clinical trial process on both scientific and cost effective grounds while moving more towards a more patient-centered trial experience. This workshop convened experts in the field of clinical trials and digital health technology to identify best practices, gaps, barriers, and future priorities for leveraging digital technologies for clinical trials.
Recap
Background
Clinical trial research is a key component of the NIH research portfolio, and using digital technology to conduct research could be transformative. Digital technology has the potential not only to reduce the cost and time for research, but it may also benefit patients by offering research opportunities that are more patient-centered with the ability to quickly address critical health-related questions.
The use of advanced analytics, such as artificial intelligence (AI), can facilitate better screening of patients, ensuring that representative groups of appropriate participants will be selected for trial interventions, and may predict response to interventions. Likewise, the use of long-distance communications technology, such as FaceTime, Skype, telehealth services, and other types of virtual visits, can assure more complete patient follow-ups — and in the end, more successful trial outcomes.
Before making any decisions about how to advance the use of this technology, however, researchers must consider a host of issues, including racial, ethnic, and socioeconomic equity, aging populations, gender differences, cultural norms, and participant preferences that might influence access and utilization, and how computational simulations could be used to reduce the sample size and length of trials.
Workshop Objectives
- Determine how best to leverage digital technology to transform clinical trials (e.g., decrease cost, improve enrollment and retention, adherence).
- Review best practices that enhance the design and conduct of clinical trials, such as the use of videos, mobile apps, text-based messaging, wearable sensors, and other platforms.
- Determine how to increase participant diversity and curb the "digital divide".
- Determine what can be done now and what are future priorities.
- Discuss implementation strategies using digital technology in future clinical trials, including workforce considerations and training needs.
Workshop Outcomes
Objective | Strategies |
---|---|
1. Leverage digital technology to transform clinical trials |
|
2. Enhance clinical trials with technology |
|
3. Increase participant diversity |
|
4. Implementation strategies using digital technology; what can be done now and future priorities |
What can be done now: Form cross-disciplinary partnerships with industry, government and academia to learn and work through complex processes with digital trials. This partnership would work towards the following:
What can be done in the future:
|
5. Implementation strategies including workforce considerations |
|
WORKSHOP CHAIR
- Robert Califf, MD, MACC; Professor of Medicine, Division of Cardiology, Duke University; Verily
WORKSHOP LEADERS
- Wendy J. Nilsen, PhD, Smart and Connected Health Program, NSF
- Erin Iturriaga, DNP, MSN, RN, Division of Cardiovascular Sciences, NHLBI
- Rebecca Campo, PhD, Division of Cardiovascular Sciences, NHLBI
- Patrice Desvigne-Nickens, MD, Division of Cardiovascular Sciences, NHLBI
- Yves Rosenberg, MD, MPH, Division of Cardiovascular Sciences, NHLBI
WORKSHOP SPEAKERS/MODERATORS IN ORDER LISTED IN WORKSHOP AGENDA
- David Goff, MD, PhD, Division Director, Division of Cardiovascular Sciences, NHLBI
- Walter (Rance) Cleaveland, PhD, Division Director, Computing and Information Science and Engineering, NSF
- Steven Steinhubl, MD, Director of Digital Medicine, Scripps Research Translational Institute
- Amy Abernethy, MD, PhD, Deputy Commissioner, FDA
- Pamela Tenaerts, MD, MBA, Executive Director, Clinical Trial Transformation Initiative, Duke University
- Mark Pletcher, MD, MPH, Director Engagement of Participants and mHealth Data Collection, University of California San Francisco
- Naveen Pereira, MD, FACC, FAHA, Mayo Clinic Rochester
- Craig Lipset, MBA, Pfizer
- John Wilbanks, BA, Chief Commons Officer, Sage Bionetworks
- Gil Alterovitz, PhD, Harvard University
- Scarlet Shore, Verily
- Beth Mynatt, PhD, Institute for People and Technology, Georgia Tech
- Robert Harrington, MD, Chair, Department of Medicine, Stanford University; President, American Heart Association
- Mintu Turakhia, MD, MAS, Director of Center for Digital Health, Stanford University
- Ken Mandl, MD, MPH, Harvard University/Boston Children’s
- Adrian Hernandez, MD, Duke University
- Kenzie Preston, PhD, National Institute on Drug Abuse
- Bonnie Spring, PhD, Northwestern University
- Steven Grinspoon, MD, Professor of Medicine, Harvard Medical School
- Don S. Dizon, MD, FACP, FASCO, Director of Medical Oncology, Rhode Island Hospital; Professor of Medicine, Brown University
- Harmony Reynolds, MD, Associate Professor of Medicine, NYU School of Medicine
- Luis Belen, Chief Executive Officer, National Health IT Collaborative for the Underserved
- Kandi Velarde, MPH, Veterans Administration
- Sara Czaja, PhD, Cornell University
- Herman Taylor, MD, Director, Cardiovascular Research Institute, Morehouse School of Medicine
- Sheila Prindiville, MD, MPH, Director, Coordinating Center for Clinical Trials, Office of the Director, National Cancer Institute (NCI)
- Harlan Krumholz, MD, Professor of Medicine, Yale University; Director, Yale-New Haven Hospital Center for Outcomes Research and Evaluation
- Benjamin Marlin, PhD, College of Information and Computer Sciences, University of Massachusetts at Amherst
- Predrag Klasjna, PhD University of Michigan
- Bharat Rao, PhD, KPMG
- Teresa Zayas-Caban, PhD, Office of the National Coordinator for Health Information Technology, U.S. Department of Health and Human Services (HHS)
- Bakul Patel, PhD, Center for Devices and Radiologic Health, FDA
- Ivor Prichard, PhD, Office of Human Research Protection, HHS
- Anna Kravets, PhD, Merck
- Omer Inan, PhD, School of Electrical and Computer Engineering, Georgia Tech
FEDERAL WORKING GROUP PARTICIPANTS
- Dana Wolff-Hughes, PhD, NIH Office of Behavioral and Social Sciences Research (OBSSR)
- Julie Bamdad, MSE, Division of Lung Disease, NHLBI
- Katharine Cooper-Arnold, MPH, Division of Cardiovascular Sciences, NHLBI
- Brad Newsome, PhD, Center for Translational Research and Implementation Science, NHLBI
- Rebecca Roper, MS, MPH, Center for Translational Research and Implementation Science, NHLBI
- Chris Sasiela, PhD, RAC, Office of Translational Alliances and Coordination, NHLBI
- Holly Nicastro, PhD, Division of Cardiovascular Sciences, NHLBI
- Albert Lee, PhD, Division of Cardiovascular Sciences, NHLBI
- Nicole Redmond, MD, PhD, MPH, Division of Cardiovascular Sciences, NHLBI
- Vandana Sachdev, MD, Division of Cardiovascular Sciences, NHLBI
- Paula Schum, MSN, RN, Division of Cardiovascular Sciences, NHLBI
- Susan Czajkowski, PhD, Chief of the Health Behaviors Research Branch, National Cancer Institute (NCI)
- April Oh, PhD, Health Communication and Informatics Research Branch, NCI
- Tiffani Lash, PhD, National Institute of Biomedical Imaging and Bioengineering (NIBIB)
- Richard Conroy, PhD, Office of Strategic Coordination, NIH Common Fund
- Courtney Aklin, PhD, Chief of Staff, National Institute on Minority Health and Health Disparities (NIMHD)
- Beda Jean-Francois, PhD, Clinical and Health Services Research Division, NIMHD
- Valerie Florance, PhD, Extramural Program Director, National Library of Medicine (NLM)
- Nick Langhals, PhD, Division of Translational Research, National Institute of Neurologic Disorders and Stroke (NINDS)
- Codrin Lungu, MD, Division of Clinical Research, NINDS
Agenda
9:00 - 9:10 AM
-
Welcome and Logistics
9:10 - 9:25 AM
-
Opening Remarks from the Division Director of NHLBI and NSF Division Director for Computer and Information Science and Engineerin
Investment in Clinical Trials: A Path Forward
David Goff, MD, PhD; Director, Division of Cardiovascular Sciences, National Heart, Lung, Blood Institute
Walter (Rance) Cleaveland, PhD; Director, Division of Computing and Communication Foundations, National Science Foundation
9:25 - 9:50 AM
-
Workshop Objectives, Charge, and Presentation
Digital Clinical Trials and the 21st Century Cures Act
Robert M. Califf, MD, MACC; Duke University
9:50 – 10:30 AM
-
KEYNOTE SESSION
Digital Clinical Trials: It’s Not (all) About The Tech
Steven Steinhubl, MD; Scripps Research Translational Institute - Director of Digital Medicine
Digital Clinical Trials: It’s Not (all) About The Tech (Part Deux)
Amy Abernethy, MD, PhD: Deputy Commissioner, Food and Drug Administration
10:30 – 10:45 AM
-
MORNING BREAK
10:45 AM – 12:10 PM
-
SESSION 1
CURRENT STATUS OF DIGITAL TRIALS AND THE PATH FORWARD
Session Moderator: Pamela Tenaerts, MD - Executive Director, Clinical Trial Transformation Initiative (CTTI)
Clinical Trials Transformation Initiative: Decentralized Clinical Trials and Mobile Technologies
Pamela Tenaerts, MD, MBA; Duke University
Direct Engagement of Participants and mHealth Data Collection using The Eureka Research Platform
Mark Pletcher, MD, MPH; University California San Francisco
Trials, Tribulations, Victories - Transitioning a Clinical Trial to a Registry Using Digital technology
Naveen Pereira, MD; Mayo Rochester
What Makes a Digital Trial in Medicine Development?
Craig Lipset, MBA; Pfizer
PANEL DISCUSSION
12:10 – 12:45 PM
-
LUNCH BREAK
12:45 – 1:45 PM
-
SESSION 2
RECRUITMENT AND RETENTION IN DIGITAL TRIALS
Session Moderator: John Wilbanks, Chief Commons Officer at Sage Bionetworks
Ethics Frameworks for Digital Clinical Trials
John Wilbanks, B.A.; Sage Bionetworks
Recruitment with social media, digital registries, EHR and other digital strategies
Gil Alterovitz, PhD; Harvard University
A Patient-Centric Approach to Clinical Research
Scarlet Shore; Verily
Techniques to Improve Patient Recruitment, Engagement and Retention in Digital Trials
Beth Mynatt, PhD; Institute for People and Technology (IPaT), Georgia Tech
PANEL DISCUSSION
1:45 – 3:15 PM
-
SESSION 3
DELIVERING INTERVENTIONS IN DIGITAL SPACE
Session Moderator: Robert Harrington, MD; Professor of Medicine and Chairman of the Department of Medicine at Stanford University Stanford University, President, American Heart Association
Measuring Interventions, Outcomes and Biomarkers Digitally
Mintu Turakhia, MD, MAS; Director of Center for Digital Health Stanford University
A SMART Approach to Clinical Trial Data Generation and Workflow: A Standards-based Interface to Health Systems and the Patient
Ken Mandl, MD, MPH; Harvard University/Boston Children’s (Pediatric Perspective)
Bridging the Digital Divide in Health Systems for Clinical Trials
Adrian Hernandez, MD; Duke University (Adult Perspective)
Navigating Safety Monitoring in Digital Clinical Trials
Kenzie Preston, PhD; National Institute on Drug Abuse/National Institutes of Health
Strategies for Maintaining Participant Engagement with Digital Trials
Bonnie Spring, PhD; Northwestern University
PANEL DISCUSSION
3:15 – 3:35 PM
-
CLINICAL TRIALIST PANEL DISCUSSION
- Steven Grinspoon, MD; Professor of Medicine, Harvard Medical School
- Don S. Dizon, MD, FACP, FASCO; Director of Medical Oncology, Rhode Island Hospital, Professor of Medicine, Brown University
- Harmony Reynolds, MD, Saul J. Farber Associate Professor of Medicine at NYU School of Medicine
3:35 – 3:45 PM
-
AFTERNOON BREAK
3:45 – 5:00 PM
-
SESSION 4
ARE WE WIDENING OR BRIDGING A DIGITAL DIVIDE WITH DIGITAL CLINICAL TRIALS?
Session Moderator: Luis Belen; Chief Executive Officer at National Health IT Collaborative for the Underserved
Title: pending
Kandi Verlarde, MPH; VA Cooperative Studies Program
Older Adults and Digital Research: What Have We Learned and Where Do We Need to Go
Sara Czaja, PhD; Cornell University
Access, Utilization Patterns, and Preferences Among Subgroups That Can Lead to Differential Benefits or Disparities
Herman Taylor, MD; Director of Cardiovascular Research Institute, Morehouse School of Medicine
PANEL DISCUSSION
5:00 PM
-
AJOURN DAY ONE
9:00 - 9:15 AM
-
Opening Remarks from the Director of NCI’s Coordinating Center for Clinical Trials (CCCT}
Leveraging Digital Technology for Cancer Clinical Trials
Sheila Prindiville, MD, MPH; Director, Coordinating Center for Clinical Trials, Office of the Director, National Cancer Institute
9:15 – 10:15 AM
-
SESSION 5
DIGITAL TRIAL ANALYTICS
Session Moderator: Dr. Harlan Krumholz, MD; Professor of Medicine, Yale University, Director of the Yale-New Haven Hospital Center for Outcomes Research and Evaluation
Advanced Analytics Including Artificial Intelligence
Benjamin Marlin, PhD; College of Information and Computer Sciences at UMass Amherst
Learning How and When to Optimally Intervene: Trials and Analytics for the Design of Precision Behavioral Interventions
Predrag Klasjna, PhD; University of Michigan
DIGITAL TRIAL ANALYTICS: Analytics at Scale with Real World Data
Bharat Rao, PhD; KPMG
PANEL DISCUSSION
10:15 – 11:15 AM
-
SESSION 6
ENVIRONMENTAL AND REGULATORY ASPECTS OF DIGITAL CLINICAL TRIALS
Session Moderator: Teresa Zayas-Caban, PhD; Office of the National Coordinator
FDA Mobile Digital Health Guidance
Bakul Patel, PhD; Food and Drug Administration, Center for Devices and Radiologic Health
Digital Clinical Trials and Human Research Subject Protections: Some Thoughts
Ivor Pritchard, PhD; Office of Human Research Protection, Health and Human Services
PANEL DISCUSSION
11:15 AM – 12:30 PM
-
SESSION 7
Workshop Summary: Critical Implications, Remaining Questions & Digital Trial Needs
Session Moderator: Omer Inan, PhD; Georgia Tech, School of Electrical and Computer Engineering
Clinical Trialist Panel Discussion:
Steven Grinspoon, MD; Professor of Medicine, Harvard Medical School
Don S. Dizon, MD, FACP, FASCO; Director of Medical Oncology, Rhode Island Hospital, Professor of Medicine, Brown University
Harmony Reynolds, MD, Saul J. Farber Associate Professor of Medicine at NYU School of Medicine
- Critical Implications for Clinical Trials
- Digital Trial Needs
- Remaining Questions